American Society of Hirudotherapy

HnSaratin

Hirudo nipponia saratin homolog — Cheng 2023 cloning + recombinant production demonstrates collagen-binding antiplatelet activity.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • HnSaratin12.4 kDa
Molecular weight (kilodaltons) of HnSaratin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

HnSaratin's recombinant antiplatelet activity in rats does NOT establish clinical efficacy. No FDA-approved derivative; H. nipponia is not on the FDA K040187 cleared device species list.

Molecular Profile

Category
Antiplatelet
Evidence tier
Preclinical
Molecular weight
12,370 Da
Source species
Hirudo nipponia
Discovered
2023 · Cheng B et al.

Biological Targets

  • → collagen (vWF / collagen interaction); platelet adhesion

Key Citations

  1. Cheng B et al. (2023), Gene · PMID 36996929

External Resources

    Related Antiplatelet Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.